<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68799">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02210169</url>
  </required_header>
  <id_info>
    <org_study_id>Vanc_IIV vs CIV</org_study_id>
    <nct_id>NCT02210169</nct_id>
  </id_info>
  <brief_title>RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates</brief_title>
  <official_title>A Randomised Controlled Trial (RCT) of Continuous and Intermittent Infusion of Vancomycin in Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Murdoch Childrens Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mercy Hospital for Women, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Murdoch Childrens Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Babies aged 0 to 90 days with a suspected infection requiring treatment with vancomycin will
      be recruited. They will be randomised to receive vancomycin as an intermittent infusion
      (over 1 hour) or as a continuous infusion (over 24 hours). The hypothesis is that
      administering vancomycin as a continuous infusion will result in improved attainment of
      target concentrations in blood at steady state (when the drug is in equilibrium) compared to
      intermittent infusion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of neonates achieving target vancomycin concentrations in blood at steady state (48 hours)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Sepsis</condition>
  <condition>Infection</condition>
  <condition>Bacteremia</condition>
  <arm_group>
    <arm_group_label>Intermittent infusion of vancomycin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Vancomycin will be administered intravenously over 1 hour. Doses will be given from one to four times a day according to corrected gestational age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous infusion of vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A loading dose of vancomycin will be given over 1 hour followed by a continuous infusion of vancomycin over a 24 hour period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continuous infusion of vancomycin</intervention_name>
    <description>Continuous infusion of vancomycin will be given as a loading dose over 1 hour then as a continuous infusion over a 24-hours period.</description>
    <arm_group_label>Continuous infusion of vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Neonates in the neonatal unit with an infection requiring treatment with vancomycin as
        determined by the treating physician.

        Exclusion Criteria:

          -  Infants born at a gestational age &lt; 25 weeks.

          -  Allergy to vancomycin or other glycopeptide antibiotic

          -  Vancomycin administered within the previous 72 hours

          -  Renal impairment

          -  Prior enrolment in the study

          -  Need for drug that is incompatible with vancomycin (if not other IV line is
             available)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda Gwee, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Murdoch Children's Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Gwee, MBBS</last_name>
    <phone>9345 5522</phone>
    <email>amanda.gwee@rch.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nigel Curtis, PhD</last_name>
    <phone>9345 5522</phone>
    <email>nigel.curtis@rch.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Royal Children's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Gwee</last_name>
      <email>amanda.gwee@rch.org.au</email>
    </contact>
    <investigator>
      <last_name>Nigel Curtis</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noel Cranswick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital for Women</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dan Casalaz</last_name>
      <email>DCasalaz@mercy.com.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 4, 2016</lastchanged_date>
  <firstreceived_date>August 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
